Literature DB >> 18007147

Results communication and patient education after screening for possible hemochromatosis and iron overload: experience from the HEIRS Study of a large ethnically and linguistically diverse group.

Ann P Walker1, Diane C Tucker, Mark A Hall, Kurt Lohman, Helen Harrison, Barbara W Harrison, Jacob Reiss, Ronald T Acton, Paul C Adams, Sharmin Diaz, Joan Holup, Elizabeth Thomson, Shellie D Ellis, Christine E McLaren.   

Abstract

PURPOSE: We assessed the effectiveness of educational interventions for conveying clinical findings and information about hereditary hemochromatosis (HH) and iron overload (IO) to individuals evaluated clinically after initial screening for HH/IO with serum ferritin (SF) concentration, transferrin saturation (TS), and HFE genotyping.
METHODS: A questionnaire mailed to 2300 cases and controls 1 month after a letter summarizing clinical findings measured understanding of results and recommendations, knowledge of HH/IO, and satisfaction with information received.
RESULTS: Of 1622 (70.5%) participants completing relevant items, 83.6% were satisfied with receiving initial screening results by mail, 93.4% found information clear and easy to understand, 89.2% generally felt they got enough information, but 47.5% still had questions. C282Y/C282Y homozygosity with normal TS/SF predicted the best understanding of genetic results. Many with no mutations thought relatives were at risk. Iron levels created most confusion, and a third incorrectly recalled treatment recommendations. Having any abnormal result, lower education, older age, and being non-white, and/or non-English speaking predicted lower understanding.
CONCLUSIONS: Combining genotypic and phenotypic screening for HH/IO creates additional difficulties in communicating results-particularly to those with low health literacy. Explaining aberrant iron TS and SF levels and low-risk genotypes, follow-up recommendations, and risk to relatives will need creative, culturally appropriate strategies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18007147     DOI: 10.1097/gim.0b013e318159a303

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  4 in total

1.  Effect of ambiguous hemochromatosis gene test results on physician utilization.

Authors:  Mark Speechley; David Alter; Helen Guo; Helen Harrison; Paul C Adams
Journal:  Med Care       Date:  2012-05       Impact factor: 2.983

2.  The Clinical Sequencing Evidence-Generating Research Consortium: Integrating Genomic Sequencing in Diverse and Medically Underserved Populations.

Authors:  Laura M Amendola; Jonathan S Berg; Carol R Horowitz; Frank Angelo; Jeannette T Bensen; Barbara B Biesecker; Leslie G Biesecker; Gregory M Cooper; Kelly East; Kelly Filipski; Stephanie M Fullerton; Bruce D Gelb; Katrina A B Goddard; Benyam Hailu; Ragan Hart; Kristen Hassmiller-Lich; Galen Joseph; Eimear E Kenny; Barbara A Koenig; Sara Knight; Pui-Yan Kwok; Katie L Lewis; Amy L McGuire; Mary E Norton; Jeffrey Ou; Donald W Parsons; Bradford C Powell; Neil Risch; Mimsie Robinson; Christine Rini; Sarah Scollon; Anne M Slavotinek; David L Veenstra; Melissa P Wasserstein; Benjamin S Wilfond; Lucia A Hindorff; Sharon E Plon; Gail P Jarvik
Journal:  Am J Hum Genet       Date:  2018-09-06       Impact factor: 11.025

3.  Hereditary hemochromatosis: insights from the Hemochromatosis and Iron Overload Screening (HEIRS) Study.

Authors:  Gordon D McLaren; Victor R Gordeuk
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2009

4.  Preferences for return of germline genome sequencing results for cancer patients and their genetic relatives in a research setting.

Authors:  Megan C Best; Phyllis Butow; Jacqueline Savard; Chris Jacobs; Nicole Bartley; Grace Davies; Christine E Napier; Mandy L Ballinger; David M Thomas; Barbara Biesecker; Katherine M Tucker; Ilona Juraskova; Bettina Meiser; Timothy Schlub; Ainsley J Newson
Journal:  Eur J Hum Genet       Date:  2022-03-11       Impact factor: 5.351

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.